Compare Abbott Laboratories (ABT) vs Super Micro Computer Inc (SMCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Super Micro Computer Inc — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while Super Micro Computer Inc trades at $27.65 (market cap $16.98B). The key difference: Abbott Laboratories is far larger — about 9.8× Super Micro Computer Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals.
| ABT | SMCI | |
|---|---|---|
Market Cap | $166.94B | $16.98B |
Sector | Health | Technology |
52-Week High | $136.62 | $60.71 |
52-Week Low | $82.57 | $20.53 |
Enterprise Value | $193.69B | $24.50B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Super Micro Computer (SMCI) trades at $27.19, down 0.11% with bearish technical signals. The stock faces headwinds from a Taiwan probe into alleged AI chip smuggling, contributing to recent volatility. Fundamentally, SMCI shows strong revenue growth with $22B in 2025 and $33.7B projected for 2026, though profit margins compressed from 4.77% to 3.7%. Valuation appears attractive with P/E of 14.31 and P/S of 0.54, while recent earnings beat expectations in two of the last three quarters.
The outlook remains cautious due to regulatory risks and negative technical momentum. Analyst consensus is mixed with 36% buy ratings and a $36.43 price target suggesting 34% upside. Key risks include the ongoing Taiwan investigation, competitive pressures in AI infrastructure, and cash flow volatility with projected negative operating cash flow in 2026. The stock presents a value opportunity but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →
